MMM

Post-Solventum (the Health Care spin completed April 1, 2024), 3M is now a tighter three-segment industrial — Safety & Industrial, Transportation & Electronics, and Consumer. The headline FY2025 GAAP numbers look ugly (net income -22.1% to $3.25B, diluted EPS -20.5% to $6.00), but the MD&A makes clear this is almost entirely special items: GAAP EPS of $6.00 versus adjusted $8.06, and GAAP operating margin of 18.6% versus adjusted 23.4%. The drag is the 2025 PFAS-related New Jersey settlement, site-remediation updates, manufactured-PFAS exit costs, a divestiture charge, and transformation costs. On an adjusted basis the business is actually improving — EPS +10%, operating margin +2.0 ppts — on productivity and lower restructuring. The market is clearly looking through to adjusted: $160.60 is ~20x adjusted EPS, a reasonable multiple for a recovering blue-chip industrial.

The quality of the underlying franchise is real but the trajectory is thin. Revenue has been stuck at $24.6–24.9B for three straight years; FY2025's +1.5% total and +0.9% organic growth reflect strength in safety/general industrial offset by known softness in auto aftermarket, roofing granules, commercial vehicles, and consumer. Cash generation improved (operating cash flow +26.8% to $2.31B against just $910M of capex), but capital returns are running hot: $3.25B of buybacks (+80.5%) plus $1.56B of dividends total $4.81B — well above the ~$1.4B of free cash flow — supported by monetizing the retained Solventum stake (a 'gain on the sale of an investment' the filing flags). That is not a durable funding source. The balance sheet optics are alarming on the surface — stockholders' equity of just $4.70B, liabilities/equity of 7.02x, ROE of 69.1% — but the equity base is depressed by cumulative legal charges (the -$7.00B FY2023 loss) and aggressive buybacks, so the 69.1% ROE is a denominator artifact, not genuine capital efficiency.